Fuyuan Pharmaceutical: Wholly-owned subsidiary Bromhexine Hydrochloride Oral Solution obtained registration certificate.

Fuyuan Pharmaceuticals announced that its wholly-owned subsidiary, Anhui Fuyuan, recently received the drug registration certificate for the oral solution of bromhexine hydrochloride, with a specification of 200ml:160mg, issued by the National Medical Products Administration. This drug is used for symptomatic treatment of various respiratory system diseases and is considered equivalent through consistency evaluation. Anhui Fuyuan submitted the application for acceptance on June 26, 2024, with a total research and development investment of 1.1143 million yuan by the announcement date. The sales revenue of this solution in the first three quarters of 2025 is approximately 28.55 million yuan. Obtaining the certificate will enrich the product line and enhance competitiveness, but sales are uncertain.